Novel β-Lactam/β-Lactamase Inhibitors Versus Best Available Therapy on the Mortality-Related Carbapenem-Resistant Enterobacterales Infection: A Systematic Review and Meta-Analysis

Basim Raddam Al Shammari

Open source

DOI
10.3390/antibiotics15090928
Published
2026-09-18
Container
Antibiotics
Publisher
MDPI AG
Open access
unknown

Credibility signals

uncertain Score 64/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

Cite this work

BibTeX

@article{allodium:10.3390/antibiotics15090928,
  title = {Novel β-Lactam/β-Lactamase Inhibitors Versus Best Available Therapy on the Mortality-Related Carbapenem-Resistant Enterobacterales Infection: A Systematic Review and Meta-Analysis},
  author = {Basim Raddam Al Shammari},
  year = {2026},
  journal = {Antibiotics},
  doi = {10.3390/antibiotics15090928},
  url = {https://doi.org/10.3390/antibiotics15090928}
}

RIS

TY  - JOUR
TI  - Novel β-Lactam/β-Lactamase Inhibitors Versus Best Available Therapy on the Mortality-Related Carbapenem-Resistant Enterobacterales Infection: A Systematic Review and Meta-Analysis
AU  - Basim Raddam Al Shammari
PY  - 2026
JO  - Antibiotics
DO  - 10.3390/antibiotics15090928
UR  - https://doi.org/10.3390/antibiotics15090928
ER  - 

APA

Shammari, B. R. A. (2026). Novel β-Lactam/β-Lactamase Inhibitors Versus Best Available Therapy on the Mortality-Related Carbapenem-Resistant Enterobacterales Infection: A Systematic Review and Meta-Analysis. Antibiotics. https://doi.org/10.3390/antibiotics15090928

Source records